A therapeutic agent comprising a RET kinase inhibiting substance intended for use in a method of treating a thyroid carcinoma, wherein the RET kinase inhibiting substance is at least one compound selected from the group consisting of de: 4- (3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide; 4- (3-chloro-4- (ethylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide; N6-methoxy-4- (3-chloro-4 - (((cyclopropylamino) carbonyl) amino) phenoxy) -7-methoxy-6-quinolinecarboxamide; 4- (3-chloro-4- (methylaminocarbonyl) aminophenoxy) -7-methoxy-6-quinolinecarboxamide; N6-methoxy-4- (3-chloro-4 - (((ethylamino) carbonyl) amino) phenoxy) -7-methoxy-6-quinolinecarboxamide; and N- {2-chloro-4 - [(6,7-dimethoxy-4-quinolyl) oxy] phenyl} -N '- (5-methyl-3-isoxazolyl) urea; a pharmacologically acceptable salt thereof or a solvate thereof.
展开▼
